Skip to content
ppharmaranks
Menu
CompaniesProductsDrug classesConditionsBest by conditionTreatmentsInteraction checkerFood & medicinesWhat pharmacies payPill identifierMedicines & breastfeedingChildren’s dosage chartsDo medicines expire?Crushing & splitting pillsHow long meds take to workAlternating Tylenol & ibuprofenDrug recallsSupplementsSafety & lawsuitsGuidesA–ZHow we rate

RESTASIS MULTIDOSE vs SANDIMMUNE

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 23, 2026·How we rate
restasis multidosesandimmune

Rating

72/100
70/100

Pharmacy pays

~$52.85 /30
~$52.85 /30

Type

RX
RX

Active ingredient

CYCLOSPORINE
CYCLOSPORINE

Manufacturer

Abbvie
Novartis

Dosage forms

Emulsion
Capsule, Injectable

Drug class

Calcineurin Inhibitor Immunosuppressant
Calcineurin Inhibitor Immunosuppressant

Boxed warning

None
None

Half-life

about 8.4 hours (range 5 to 18 hours)
about 8.4 hours (range 5 to 18 hours)

Treats

Rheumatoid Arthritis, Focal Segmental Glomerulosclerosis, Systemic Lupus Erythematosus
Rheumatoid Arthritis, Focal Segmental Glomerulosclerosis, Systemic Lupus Erythematosus

Frequently asked questions

Which is better-rated, Restasis Multidose or Sandimmune?

By our independent rating, Restasis Multidose scores higher — 3.6 vs 3.5 out of 5 for Sandimmune. Ratings are based on FDA regulatory (recall-safety) data.

Which is cheaper, Restasis Multidose or Sandimmune?

Pharmacies pay about the same to acquire either one — roughly $52.85 for a 30-count supply, per the CMS NADAC survey. That is not what you will be charged: your price is set by your insurer and the pharmacy, not by what the drug cost them.

What is the difference between Restasis Multidose and Sandimmune?

Both Restasis Multidose and Sandimmune share the active ingredient Cyclosporine.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.